Supernus Pharmaceuticals, Inc. (SUPN)

Supernus Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	668	661.82	607.52	667.24	579.78	520.4
Revenue Growth (YoY)	11.82%	8.94%	-8.95%	15.09%	11.41%	32.50%
Cost of Revenue	77.36	77.91	83.78	87.22	75.06	52.46
Gross Profit	590.64	583.91	523.74	580.02	504.71	467.94
Selling, General & Admin	343.61	335.78	336.36	377.22	304.76	200.68
Research & Development	110.79	108.8	91.59	74.55	90.47	75.96
Operating Expenses	532.03	522.56	510.34	534.4	425.22	292.34
Operating Income	58.61	61.36	13.4	45.61	79.5	175.6
Interest Expense	-	-	-2.42	-7.07	-23.42	-23.75
Interest & Investment Income	1.03	-	-	-	10.22	14.35
Other Non Operating Income (Expenses)	16.2	16.2	10.45	21.68	-	-
EBT Excluding Unusual Items	75.83	77.55	21.44	60.22	66.3	166.2
Gain (Loss) on Sale of Investments	0.01	0.01	-	0.01	0.35	4.35
Asset Writedown	-	-	-20.19	-	-	-
Other Unusual Items	-2.65	6.11	1.52	0.51	6.53	-1.9
Pretax Income	91.8	97.87	2.77	60.74	73.18	168.65
Income Tax Expense	29.88	24.01	1.45	0.03	19.75	41.7
Net Income	61.91	73.87	1.32	60.71	53.42	126.95
Net Income to Common	61.91	73.87	1.32	60.71	53.42	126.95
Net Income Growth	-	5512.84%	-97.83%	13.64%	-57.92%	12.29%
Shares Outstanding (Basic)	55	55	55	54	53	53
Shares Outstanding (Diluted)	56	56	56	62	54	54
Shares Change (YoY)	2.52%	0.81%	-10.01%	13.47%	1.24%	-0.24%
EPS (Basic)	1.12	1.34	0.02	1.13	1.01	2.41
EPS (Diluted)	1.11	1.32	0.02	1.04	0.98	2.36
EPS Growth	-	6500.00%	-98.08%	6.32%	-58.48%	12.38%
Free Cash Flow	163.35	171.23	110.53	116.41	125.08	134.71
Free Cash Flow Per Share	2.92	3.06	1.99	1.89	2.30	2.51
Gross Margin	88.42%	88.23%	86.21%	86.93%	87.05%	89.92%
Operating Margin	8.77%	9.27%	2.21%	6.84%	13.71%	33.74%
Profit Margin	9.27%	11.16%	0.22%	9.10%	9.21%	24.39%
Free Cash Flow Margin	24.45%	25.87%	18.19%	17.45%	21.57%	25.89%
EBITDA	138.66	141.77	98.26	131.16	112.09	193.74
EBITDA Margin	20.76%	21.42%	16.17%	19.66%	19.33%	37.23%
D&A For EBITDA	80.05	80.41	84.86	85.54	32.6	18.14
EBIT	58.61	61.36	13.4	45.61	79.5	175.6
EBIT Margin	8.77%	9.27%	2.21%	6.84%	13.71%	33.74%
Effective Tax Rate	32.55%	24.53%	52.47%	0.05%	26.99%	24.73%
Revenue as Reported	668	661.82	607.52	667.24	579.78	520.4

Updated May 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q